| Literature DB >> 17727713 |
Andrew W Bergen1, Andrea Baccarelli, Timothy K McDaniel, Kenneth Kuhn, Ruth Pfeiffer, Jerry Kakol, Patrick Bender, Kevin Jacobs, Bernice Packer, Stephen J Chanock, Meredith Yeager.
Abstract
BACKGROUND: Sequence and transcriptional variability within and between individuals are typically studied independently. The joint analysis of sequence and gene expression variation (genetical genomics) provides insight into the role of linked sequence variation in the regulation of gene expression. We investigated the role of sequence variation in cis on gene expression (cis sequence effects) in a group of genes commonly studied in cancer research in lymphoblastoid cell lines. We estimated the proportion of genes exhibiting cis sequence effects and the proportion of gene expression variation explained by cis sequence effects using three different analytical approaches, and compared our results to the literature.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17727713 PMCID: PMC2077339 DOI: 10.1186/1471-2164-8-296
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Genes chosen for analysis of cis sequence effects on gene expression
| ALDH2 | 134.3 | 84.2 | 94.9 | 63.6 | 43,438 | 4 |
| BCL2L1 | 274.8 | 79.1 | 62.8 | 26.2 | 58,393 | 3 |
| BIC | 2451.0 | 585.9 | 63.9 | 22.2 | 12,968 | 22 |
| BIRC3 | 813.4 | 244.4 | 70.1 | 27.6 | 20,271 | 2 |
| BLM | 177.3 | 59.4 | 81.4 | 32.7 | 97,996 | 24 |
| CCNA2 | 343.7 | 111.1 | 66.1 | 27.3 | 6,367 | 4 |
| CCND3 | 807.7 | 257.4 | 86.3 | 30.5 | 6,880 | 6 |
| CDKN1B | 161.2 | 44.6 | 75.4 | 24.0 | 4,994 | 3 |
| CHEK1 | 173.2 | 62.4 | 75.9 | 31.2 | 29,300 | 2 |
| CYP1B1 | 310.7 | 206.2 | 90.6 | 66.2 | 8,546 | 50 |
| EGR1 | 145.9 | 73.2 | 71.4 | 45.9 | 3,823 | 2 |
| FCGR2B | 149.2 | 56.6 | 85.0 | 36.9 | 14,867 | 9 |
| GADD45A | 314.5 | 90.2 | 82.5 | 27.9 | 3,136 | 4 |
| IFNGR1 | 662.0 | 272.4 | 92.1 | 40.4 | 21,885 | 2 |
| IFNGR2 | 852.5 | 224.8 | 85.2 | 24.3 | 34,624 | 5 |
| IRF1 | 267.4 | 57.3 | 64.7 | 20.3 | 7,647 | 5 |
| JAK1 | 161.5 | 44.2 | 71.7 | 25.1 | 51,778 | 20 |
| LMO2 | 187.4 | 124.5 | 97.1 | 68.4 | 33,711 | 8 |
| LTA | 2196.5 | 667.3 | 83.5 | 29.8 | 2,005 | 7 |
| MGMT | 417.0 | 131.5 | 93.8 | 31.3 | 230,861 | 6 |
| MSH2 | 190.0 | 52.5 | 66.8 | 23.6 | 80,097 | 3 |
| MYBL2 | 277.6 | 116.7 | 74.8 | 36.4 | 49,413 | 25 |
| MYC | 512.4 | 191.1 | 85.9 | 34.9 | 5,170 | 2 |
| NBS1 | 163.8 | 40.4 | 70.4 | 23.6 | 51,187 | 19 |
| OAS1 | 490.8 | 153.5 | 86.3 | 30.2 | 12,956 | 5 |
| PCNA | 2523.3 | 685.6 | 71.0 | 23.6 | 11,669 | 3 |
| PHB | 178.4 | 44.3 | 64.9 | 20.9 | 10,822 | 3 |
| PIM1 | 145.6 | 51.2 | 74.3 | 33.0 | 5,218 | 7 |
| PTEN | 297.7 | 65.5 | 71.8 | 20.1 | 103,207 | 5 |
| TNF | 1097.3 | 246.4 | 83.4 | 22.2 | 2,762 | 12 |
| TP73L | 110.1 | 89.0 | 97.0 | 81.0 | 265,849 | 26 |
| TYMS | 1554.5 | 399.1 | 69.8 | 22.9 | 15,841 | 19 |
SNPs & haplotypes chosen for analysis of cis sequence effects
| ALDH2 | 4 | 2 | 1 | 1 | 3 |
| BCL2L1 | 3 | 2 | 0 | 2 | 3 |
| BIC | 22 | 9 | 3 | 6 | 8 |
| BIRC3 | 2 | 2 | 0 | 2 | 3 |
| BLM | 24 | 9 | 5 | 4 | 7 |
| CCNA2 | 4 | 3 | 0 | 3 | 4 |
| CCND3 | 6 | 4 | 0 | 4 | 7 |
| CDKN1B | 3 | 3 | 0 | 3 | 6 |
| CHEK1 | 2 | 2 | 0 | 2 | 3 |
| CYP1B1 | 50 | 14 | 7 | 7 | 19 |
| EGR1 | 2 | 0 | 0 | 0 | na |
| FCGR2B | 9 | 6 | 1 | 5 | 10 |
| GADD45A | 4 | 0 | 0 | 0 | na |
| IFNGR1 | 2 | 2 | 0 | 2 | 3 |
| IFNGR2 | 5 | 2 | 0 | 2 | 3 |
| IRF1 | 5 | 1 | 1 | 0 | na |
| JAK1 | 20 | 5 | 2 | 2 | 7 |
| LMO2 | 8 | 8 | 0 | 8 | 13 |
| LTA | 7 | 10 | 4 | 6 | 9 |
| MGMT | 6 | 4 | 2 | 2 | 6 |
| MSH2 | 3 | 1* | na | na | na |
| MYBL2 | 25 | 8 | 4 | 4 | 6 |
| MYC | 2 | 1* | na | na | na |
| NBS1 | 19 | 4 | 2 | 2 | 7 |
| OAS1 | 5 | 1 | 1 | 0 | na |
| PCNA | 3 | 2 | 0 | 2 | 3 |
| PHB | 3 | 3 | 0 | 3 | 4 |
| PIM1 | 7 | 2 | 1 | 1 | 3 |
| PTEN | 5 | 3 | 0 | 3 | 4 |
| TNF | 12 | 10 | 4 | 6 | 9 |
| TP73L | 26 | 9 | 3 | 7 | 13 |
| TYMS | 19 | 4 | 3 | 1 | 4 |
*There was one SNP with maf > 5% at these two genes; tag SNP analysis was not performed. The single SNP with maf > 5% at each gene was used for SNP-based analyses.
SNP and haplotype-based cis sequence effects on gene expression*
| ALDH2 | 2 | 0.482 | 0.577 | 0.796 |
| BCL2L1 | 2 | 0.283 | 0.488 | 0.191 |
| BIC | 9 | 0.056 | ||
| BIRC3 | 2 | 0.110 | 0.550 | 0.092 |
| BLM | 9 | 0.941 | 0.266 | 0.882 |
| CCNA2 | 3 | 0.142 | 0.085 | 0.635 |
| CCND3 | 4 | 0.601 | 0.519 | 0.819 |
| CDKN1B | 3 | 0.142 | 0.059 | 0.259 |
| CHEK1 | 2 | 0.542 | 0.290 | 0.577 |
| CYP1B1 | 14 | did not compute | 0.438 | |
| FCGR2B | 6 | |||
| IFNGR1 | 2 | 0.981 | 0.854 | 0.902 |
| IFNGR2 | 2 | 0.175 | 0.096 | 0.374 |
| IRF1 | 1 | 0.160 | 0.282 | Na |
| JAK1 | 5 | 0.194 | 0.375 | 0.123 |
| LMO2 | 8 | 0.830 | 0.181 | |
| LTA | 103 | 0.785 | 0.380 | 0.992 |
| MGMT | 4 | 0.330 | 0.064 | 0.329 |
| MSH2 | 1 | 0.388 | 0.409 | Na |
| MYBL2 | 8 | 0.105 | 0.095 | |
| MYC | 1 | 0.303 | 0.409 | Na |
| NBS1 | 4 | 0.197 | ||
| OAS1 | 1 | 0.186 | 0.206 | Na |
| PCNA | 2 | 0.138 | 0.064 | |
| PHB | 3 | 0.902 | 0.651 | 0.937 |
| PIM1 | 2 | 0.689 | 0.419 | 0.721 |
| PTEN | 3 | 0.257 | 0.236 | 0.569 |
| TNF | 103 | 0.619 | 0.394 | 0.756 |
| TP73L | 9 | 0.305 | 0.563 | |
| TYMS | 4 | 0.127 | 0.100 | 0.185 |
*Statistically significant results are bolded. **See Additional file 3 for SNP details.
Figure 1Haplotype phylogenies and significant haplotype partitions at FCGR2B, PCNA and LMO2. Haplotype phylogenies are represented together with the SNP allele configuration and the count of haplotypes in the sample. Statistically significant haplotype partitions in the phylogeny are indicated by a vertical or horizontal bar, while an arrow indicates a SNP that exhibits significant association via regression analysis. The haplotypes at FCGR2B, LMO2 and PCNA were constructed using the following SNPs: rs12145988, rs17412751, rs922087, rs2298020, rs1674761, rs844; rs17352 and rs25406; and rs3740616, rs3740617, rs2273797, rs2038602, rs9282776, rs3781577, rs3758640, rs3758641.